<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399345</url>
  </required_header>
  <id_info>
    <org_study_id>M15-310</org_study_id>
    <secondary_id>2014-005280-32</secondary_id>
    <nct_id>NCT02399345</nct_id>
  </id_info>
  <brief_title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults</brief_title>
  <official_title>An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study will evaluate the safety and efficacy of co-formulated
      ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or
      without ribavirin administered for either 4 or 6 weeks in treatment naive adults with
      chronic HCV-genotype 1 infection without cirrhosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects achieving a 12-week sustained virologic response</measure>
    <time_frame>12 weeks after the last actual dose of study drug (either 16 or 18 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with on-treatment virologic failure</measure>
    <time_frame>During 4 or 6 weeks of treatment with study drug (either 4 weeks or 6 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with confirmed HCV RNA &gt;= lower limit of quantification at any time point during treatment, confirmed increase from nadir or failure to suppress during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with post-treatment relapse</measure>
    <time_frame>Up to 12 weeks after last actual dose of active study drug (either 16 or 18 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with HCV RNA less than the lower limit of quantification at the end of treatment with confirmed HCV RNA greater than or equal to the lower limit of quantification through 12 weeks post treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Hepatitis C Virus (HCV Infection Genotype 1)</condition>
  <arm_group>
    <arm_group_label>6 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Subjects will be enrolled to receive ombitasvir/paritaprevir/r with dasabuvir and SOF with RBV for six weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 - Subjects will be enrolled to receive ombitasvir/paritaprevir/r with dasabuvir and SOF with RBV for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF with RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3a: Subjects will be randomized in a 1:1 ratio to receive ombitasvir/paritaprevir/r with dasabuvir and SOF with RBV for a treatment duration of 4 or 6 weeks (determined based on the outcomes of Cohorts 1 and 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF without RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3b: Subjects will be randomized in a 1:1 ratio to receive ombitasvir/paritaprevir/r with dasabuvir and SOF without RBV for a treatment duration of 4 or 6 weeks (determined based on the outcomes of Cohorts 1 and 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>tablet</description>
    <arm_group_label>6 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>4 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF without RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <description>tablet</description>
    <arm_group_label>6 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>4 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF without RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir (SOF)</intervention_name>
    <description>tablet</description>
    <arm_group_label>6 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>4 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF without RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>tablet</description>
    <arm_group_label>6 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>4 weeks ombitasvir/paritaprevir/r, dasabuvir and SOF with RBV</arm_group_label>
    <arm_group_label>ombitasvir/paritaprevir/r dasabuvir + SOF with RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 18 years of age at time of screening

          2. Chronic HCV infection prior to study enrollment

          3. Screening laboratory results from the central clinical laboratory indicating HCV
             genotype 1 infection only

          4. Absence of cirrhosis and advanced bridging fibrosis

        Exclusion Criteria:

          1. Positive test result for Hepatitis B surface antigen (HbsAg) or HIV positive
             immunoassay

          2. Clinically significant abnormalities or co-morbidities, other than HCV infection,
             that make the subject an unsuitable candidate for this study or treatment with RBV in
             the opinion of the investigator

          3. Any current or past clinical evidence of cirrhosis such as ascites or esophageal
             varices, or prior biopsy showing cirrhosis or advanced bridging fibrosis, e.g., a
             Metavir score &gt; 2 or an Ishak score &gt; 3

          4. Use of medications contraindicated for Ombitasvir/Paritaprevir, Dasabuvir, SOF,
             ritonavir or RBV (for those that receive RBV), within 2 weeks or 10 half-lives
             whichever is longer, prior to study drug administration

          5. Current enrolment in another clinical study, previous enrolment in this study, or
             previous use of any investigational or commercially available anti-HCV agents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136598</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137903</name>
      <address>
        <city>Toronto</city>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137904</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137906</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z-2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137907</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136942</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 18, 2015</lastchanged_date>
  <firstreceived_date>March 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment naive</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
